Prostate Cancer - Results from #560

Body composition as a determinant of the therapeutic index with androgen signaling inhibition. July 26, 2024

Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective July 25, 2024

The TALAPRO-3 study design: a plain language summary. July 25, 2024

The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy - A propensity score matched longitudinal study. July 25, 2024

Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. July 25, 2024

Robust, credible, and interpretable AI-based histopathological prostate cancer grading. July 25, 2024

Enhancing Prostate Cancer Diagnosis: AI-Driven Virtual Biopsy for Optimal MRI-Targeted Biopsy Approach and Gleason Grading Strategy. July 25, 2024

Prostate cancers with distinct transcriptional programs in Black and White men. July 25, 2024

Defining the Optimal Target-to-Background Ratio to Identify Positive Lymph Nodes in Prostate Cancer Patients Undergoing Robot-Assisted [99mTc]Tc-PSMA Radioguided Surgery: Updated Results and Ad Interim Analyses of a Prospective Phase II Study - Beyond the July 24, 2024

Prostate MRI for the detection of clinically significant prostate cancer: Update and future directions. July 24, 2024

Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival. July 24, 2024

Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus. July 24, 2024

Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study. July 24, 2024

Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same? July 24, 2024

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. July 24, 2024

Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. July 23, 2024

Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. July 23, 2024

Real-world evidence of 18F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System. July 23, 2024

The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials. July 23, 2024

Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients. July 23, 2024

Page 29 of 1437